The participation of national pharmaceutical companies in the Brazilian pharmaceutical market has shown constant growth since 2002 compared to multinational companies. This evolution occurs due to sales of generic medicines, incentives for local production, appropriate public policies, and also innovation and technology that enable research to be conducted in Brazil.

According to indicators from IQVIA / ALANAC, laboratories with national capital participate in 72% of the Brazilian pharmaceutical market, in units. From 2002 to 2024, this evolution in values increased by more than 63%. Data also reveals that among the top 20 in the retail market in units, 13 are national laboratories.

Source: Medicina S/A